The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

Annual Review of Pharmacology and Toxicology

Volumn 37, Issue , 1997, Pages 143-166

  Gibbs, Jackson B ^a   Oliff, Allen ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

geranylgeranylation; ras oncogenes; signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; FARNESYL TRANS TRANSFERASE; TRANSFERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0030962347     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.37.1.143     Document Type: Review

References (125)

1. Levitzki A, Gazit A. 1995. Tyrosine kinase inhibition: an approach to drug development. Science 267:1782-88
2. Gibbs JB, Oliff A. 1994. Pharmaceutical research in molecular oncology. Cell 79:193-98
3. Clark GJ, Der CJ. 1995. ras protooncogene activation in human malignancy. In Cellular Cancer Markers, ed. CT Garrett, S Sell, pp. 17-52. Totowa, NJ: Humana
4. Barbacid M. 1987. ras Genes. Annu. Rev. Biochem. 56:779-827
5. Lowy DR, Willumsen BM. 1993. Function and regulation of Ras. Annu. Rev. Biochem. 62:851-91
6. Bernards A. 1995. Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. Biochim. Biophys. Acta 1242:43-59
7. Bos JL. 1990. ras gene mutations and human cancer. In Molecular Genetics in Cancer Diagnosis, ed. J Cossman, pp. 273-87. Amsterdam, Netherlands: Elsevier Sci.
8. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, et al. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12:144-48
9. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. 1996. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat. Genet. 12:137-43
10. Gibbs JB. 1992. Pharmacological probes of Ras function. Semin. Cancer Biol. 3:383-90
11. Gibbs JB. 1991. Ras C-terminal processing enzymes - new drug targets? Cell 65:1-4
12. Prendergast GC, Gibbs JB. 1994. Regulatory interactions in Ras signal transduction: new targets for anti-cancer intervention? BioEssays 16:187-91
13. Spaargaren M, Bischoff JR, McCormick F. 1995. Signal transduction by Ras-like GTPases: a potential target for anticancer drugs. Gene Expr. 4:345-56
14. Sattler I, Tamanoi F. 1996. Prenylation of Ras and inhibitors of prenyltransferases. In Molecular Biology Intelligence Unit Ser., ed. H Maruta. Austin, TX: RG Landes. In press
15. Omura S, Takeshima H. 1994. Farnesylprotein transferase inhibitors. Drugs Future 19:751-55
16. Hamilton AD, Sebti SM. 1995. Inhibitors of Ras farnesyltransferase as novel antitumor agents. DN&P 8:138-45
17. Graham SL. 1995. Inhibitors of protein farnesylation: a new approach to cancer chemotherapy. Exp. Opin. Ther. Patents 5:1269-85
18. Gibbs JB, Oliff A, Kohl NE. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-78
19. Manne V, Ricca CS, Brown JG, Tuomari AV, Van N, et al. 1995. Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Dev. Res. 34:121-37
20. Khosravi-Far R, Cox AD, Kato K, Der CJ. 1992. Protein prenylation: key to Ras function and cancer intervention. Cell Growth Differ. 3:461-69
21. Clarke S. 1992. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu. Rev. Biochem. 61:355-86
22. Schafer WR, Rine J. 1992. Protein prenylation: genes, enzymes, targets, and functions. Annu. Rev. Genet. 30:209-37
23. Goodman LE, Perou CM, Fujiyama A, Tamanoi F. 1988. Structure and expression of yeast DPR1, a gene essential for the processing and intracellular localization of ras proteins. Yeast 4:271-81
24. Powers S, Michaelis S, Broek D, Santa-Anna AS, Field J, et al. 1986. RAM, a gene of yeast required for a functional modification of RAS proteins and for production of mating pheromone a-factor. Cell 47:413-22
25. Bollag G, McCormick F. 1991. Regulators and effectors of ras proteins. Annu. Rev. Cell Biol. 7:601-32
26. Burgering BMT, Bos JL. 1995. Regulation of Ras-mediated signalling: more than one way to skin a cat. Trends Biochem. Sci. 20:18-22
27. Marshall MS. 1995. Ras target proteins in eukaryotic cells. FASEB J. 9:1311-18
28. Sinensky M, Lutz MJ. 1992. The prenylation of proteins. BioEssays 14:25-31
29. Maltese WA. 1990. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4:3319-27
30. Glomset JA, Gelb MH, Farnsworth CC. 1990. Prenyl proteins in eucaryotic cells: a new type of membrane anchor. Trends Biochem. Sci. 15:139-42
31. Zhang FL, Casey PJ. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:241-69
32. Casey PJ, Seabra MC. 1996. Protein prenyltransferases. J. Biol. Chem. 271:5289-92
33. Tamanoi F. 1993. Inhibitors of Ras farnesyltransferases. Trends Biochem. Sci. 18:349-53
34. Willumsen BM, Norris K, Papageorge AG, Hubbert NL, Lowy DR. 1984. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J. 3:2581-85
35. Kamiya Y, Sakurai A, Tamura S, Takahashi N, Tsuchiya E, et al. 1979. Structure of rhodotorucine A, a peptidyl factor, inducing mating tube formation in Rhodosporidium toruloides. Agric. Biol. Chem. 43:363-69
36. Ishibashi Y, Sakagami Y, Isogai A, Suzuki A. 1984. Structures of tremerogens A-9291-I and A-9291-VIII: peptidyl sex hormones of tremella brasiliensis. Biochemistry 23:1399-404
37. Anderegg RJ, Betz R, Carr SA, Crabb JW, Duntze W. 1988. Structure of Saccharomyces cerevisiae mating hormone a-factor. J. Biol. Chem. 263:18236-40
38. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. 1989. Human lamin B contains a farnesylated cysteine residue. J. Biol. Chem. 264:20422-29
39. Casey PJ, Solski PA, Der CJ, Buss JE. 1989. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA 86:8323-27
40. Hancock JF, Magee AI, Childs JE, Marshall CJ. 1989. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167-77
41. Schafer WR, Kim R, Sterne R, Thorner J, Kim S-H, et al. 1989. Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans. Science 245:379-85
42. Cox AD, Der CJ. 1992. The Ras/cholesterol connection: implications for ras oncogenicity. Crit. Rev. Oncog. 3:365-400
43. Graham SM, Cox AD, Drivas G, Rush MG, D'Eustachio P, et al. 1994. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation. Mol. Cell. Biol. 14:4108-15
44. Lopez-Barahona M, Bustelo XR, Barbacid M. 1996. The TC21 oncoprotein interacts with the Ral guanosine nucleotide dissociation factor. Oncogene 12:463-70
45. Symons M. 1995. The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Curr. Opin. Biotechnol. 6:668-74
46. Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R. 1994. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol. Cell. Biol. 14:3752-62
47. Crowell PL, Cates CA, Burke YD, Harvey K, Crowell DN, et al. 1996. Prenylation of novel oncogenic human PTP CAAX protein tyrosine phosphatases. Proc. Am. Assoc. Cancer Res. 37:576
48. ras but does not affect their function or localization. Cancer Res. 55:3295-304
49. Caplan AJ, Tsai J, Casey PJ, Douglas MG. 1992. Farnesylation of YDJ1p is required for function at elevated growth temperatures in Saccharomyces cerevisiae. J. Biol. Chem. 267:18890-95
50. Chellaiah A, Davis A, Mohanakumar T. 1993. Cloning of a unique human homologue of the Escherichia coli DNAJ heat shock protein. Biochim. Biophys. Acta 1174:111-13
51. Heilmeyer LMG Jr, Serwe M, Weber C, Metzger J, Hoffmann-Posorske E, et al. 1992. Farnesylcysteine, a constituent of the a and b subunits of rabbit skeletal muscle phosphorylase kinase: localization by conversion to S-ethylcysteine and by tandem mass spectrometry. Proc. Natl. Acad. Sci. USA 89:9554-58
52. James GL, Goldstein JL, Pathak RK, Anderson RGW, Brown MS. 1994. PxF, a prenylated protein of peroxisomes. J. Biol. Chem. 269:14182-90
53. Foster R, Hu K-Q, Lu Y, Nolan KM, Thissen J, et al. 1996. Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation. Mol. Cell. Biol. 16:2689-99
54. ras farnesyl: protein transferase by cys-AAX tetrapeptides. Cell 62:81-88
55. ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA 88:732-36
56. Schaber MD, O'Hara MB, Garsky VM, Mosser SD, Bergstrom JD, et al. 1990. Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. J. Biol. Chem. 265:14701-4
57. Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, et al. 1991. Sequence dependence of protein isoprenylation. J. Biol. Chem. 266:14603-10
58. James GL, Goldstein JL, Brown MS. 1995. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270:6221-26
59. Zhang FL, Fu H-W, Casey PJ, Bishop WR. 1996. Substitution of cadmium for zinc in farnesyl: protein transferase alters its substrate specificity. Biochemistry 35:8166-71
60. Trueblood CE, Ohya Y, Rine J. 1993. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae. Mol. Cell. Biol. 13:4260-75
61. Armstrong SA, Hannah VC, Goldstein JL, Brown MS. 1995. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J. Biol. Chem. 270:7864-68
62. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, et al. 1993. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90:2281-85
63. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, et al. 1993. Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo. J. Biol. Chem. 268:7617-20
64. Reiss Y, Brown MS, Goldstein JL. 1992. Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain, a zinc metalloenzyme. J. Biol. Chem. 267:6403-8
65. Pompliano DL, Rands E, Schaber MD, Mosser SD, Anthony NJ, et al. 1992. Steady-state kinetic mechanism of Ras farnesyl: protein transferase. Biochemistry 31:3800-7
66. Furfine ES, Leban JJ, Landavazo A, Moomaw JF, Casey PJ. 1995. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Biochemistry 34:6857-62
67. Pompliano DL, Schaber MD, Mosser SD, Omer CA, Shafer JA, et al. 1993. Isoprenoid diphosphate utilization by recombinant human farnesyl-protein transferase: interactive binding between substrates and a preferred kinetic pathway. Biochemistry 32:8341-47
68. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, et al. 1993. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-37
69. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, et al. 1993. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260:1937-42
70. Garcia AM, Rowell C, Ackermann K, Kowalczyk JJ, Lewis MD. 1993. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem. 268:18415-18
71. Bishop WR, Bond R, Petrin J, Wang L, Patton R, et al. 1995. Novel tricyclic inhibitors of farnesyl protein transferase. J. Biol. Chem. 270:30611-18
72. Williams TM, Ciccarone TM, MacTough SC, Bock RL, Conner MW, et al. 1996. 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, noncarboxylic acid inhibitors of farnesyltransferase. J. Med. Chem. 39:1345-48
73. Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, et al. 1995. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and ras processing. J. Biol. Chem. 270:660-64
74. Hunt JT, Lee VG, Leftheris K, Seizinger B, Carboni J, et al. 1996. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J. Med. Chem 39:353-58
75. Koblan KS, Culberson JC, deSolms SJ, Giuliani EA, Mosser SD, et al. 1995. NMR studies of novel inhibitors bound to farnesyl-protein transferase. Protein Sci. 4:681-88
76. Stradley SJ, Rizo J, Gierasch LM. 1993. Conformation of a heptapeptide substrate bound to protein farnesyltransferase. Biochemistry 32:12586-90
77. Patel DV, Gordon EM, Schmidt RJ, Weller HN, Young MG, et al. 1995. Phosphinyl acid-based bisubstrate analog inhibitors of ras farnesyl protein transferase. J. Med. Chem. 38:435-42
78. Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, et al. 1995. Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells. Oncogene 10:1763-79
79. Cox AD, Garcia AM, Westwick JK, Kowalczyk JJ, Lewis MD, et al. 1994. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem. 269:19203-6
80. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, et al. 1995. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. 270:26802-6
81. Lerner EC, Qian Y, Hamilton AD, Sebti SM. 1995. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem. 270:26770-73
82. V12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc. Natl. Acad. Sci. USA 93:4454-58
83. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. 1995. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 55:5310-14
84. Sun J, Qian Y, Hamilton AD, Sebti SM. 1995. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 55:4243-47
85. Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, et al. 1996. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J. Med. Chem. 39:224-36
86. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, et al. 1994. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA 91:9141-45
87. Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, et al. 1994. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 14:4193-202
88. Pai JJ-K, Bishop WR, Catino J, Kirschmeier P, Whyte D. 1996. Characterization of prenyl groups attached to K-Ras in DLD-1 human colon carcinoma cells treated with the FPT inhibitor SCH. 44342. Proc. Am. Assoc. Cancer Res. 37:503
89. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, et al. 1995. A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:5302-9
90. Van N, Ricca C, Fletcher J, Glover T, Seizinger BR, et al. 1995. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res. 55:3569-75
91. Smith MR, DeGudicibus SJ, Stacey DW. 1986. Requirement for c-ras proteins during viral oncogene transformation. Nature 320:540-43
92. Stacey DW, Roudebush M, Day R, Mosser SD, Gibbs JB, et al. 1991. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes. Oncogene 6:2297-304
93. James GL, Brown MS, Cobb MH, Goldstein JL. 1994. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells. J. Biol. Chem. 269:27705-14
94. 12]Ras is inhibited by a cytosol-localized Ras mutant. Proc. Natl. Acad. Sci. USA 86:6630-34
95. Stacey DW, Feig LA, Gibbs JB. 1991. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol. Cell. Biol. 11:4053-64
96. Michaeli T, Field J, Ballester R, O'Neill K, Wigler M. 1989. Mutants of H-ras that interfere with RAS effector function in Saccharomyces cerevisiae. EMBO J. 8:3039-44
97. Miyake M, Mizutani S, Koide H, Kaziro Y. 1996. Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable Ras Raf complex in the cytosol. FEBS Lett. 378:15-18
98. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, et al. 1996. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed Rat embryo fibroblasts. Cancer Res. 56:1727-30
99. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, et al. 1995. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55:4575-80
100. Ito T, Kawata S, Tamura S, Igura T, Nagase T, et al. 1996. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl: protein transferase inhibitor. Jpn. J. Cancer Res. 87:113-16
101. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, et al. 1995. Inhibition of famesyltranserase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1:792-97
102. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, et al. 1987. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49:465-75
103. Vogelstein B, Kinzler KW. 1993. The multistep nature of cancer. Trends Genet. 9:138-41
104. Jacks T, Weinberg RA. 1996. Cell-cycle control and its watchman. Nature 381:643-716
105. Hara M, Han M. 1995. Ras farnesyltranserase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 92:3333-37
106. Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD, et al. 1995. Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proc. Natl. Acad. Sci. USA 92:10919-23
107. Sternberg PW, Horvitz HR. 1991. Signal transduction during C. elegans vulval induction. Trends Genet. 7:366-71
108. Rubin G. 1991. Signal transduction and the fate of the R7 photoreceptor in Drosophila. Trends Genet. 7:372-77
109. Therrien M, Chang HC, Solomon NM, Karim FD, Wassarman DA, et al. 1995. KSR, a novel protein kinase required for Ras signal transduction. Cell 83:879-88
110. Hancock JF, Cadwallader K, Paterson H, Marshall CJ. 1991. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of Ras proteins. EMBO J. 10:4033-39
111. Cox AD, Hisaka MM, Buss JE, Der CJ. 1992. Specific isoprenoid modification is required for function of normal, but not oncogeneic, Ras function. Mol. Cell. Biol. 12:2606-15
112. Graham SL, deSolms SJ, Giuliani EA, Kohl NE, Mosser SD, et al. 1994. Pseudopeptide inhibitors of Ras farnesylprotein transferase. J. Med. Chem. 37:725-32
113. Rilling HC, Bruenger E, Leining LM, Buss JE, Epstein WW. 1993. Differential prenylation of proteins and lipid synthesis as a function of mevalonate concentration in CHO cells. Arch. Biochem. Biophys. 301:210-15
114. Page MJ, Aitken A, Cooper DJ, Magee AI, Lowe PN. 1990. Use of the insect-baculovirus expression system to produce lipid-modified Ras protein for electrospray mass spectrometric studies. Methods 1:221-30
115. Buss JE, Quilliam LA, Kato K, Casey PJ, Solski PA, et al. 1991. The carboxyl-terminal domain of the RAP1A KREV-1 protein is isoprenylated and supports transformation by an H-Ras RAP1A chimeric protein. Mol. Cell. Biol. 11:1523-30
116. Lebowitz PF, Davide JP, Prendergast GC. 1995. Evidence that farneslytransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol. 15:6613-22
117. Yaglom JA, Goldberg AL, Finley D, Sherman MY. 1996. The molecular chaperone Ydj1 is required for the p34CDC28-dependent phosphorylation of the cyclin Cln3 that signals its degradation. Mol. Cell. Biol. 16:3679-84
118. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, et al. 1995. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 10:2289-96
119. rho proteins. J. Biol. Chem. 267:20033-38
120. Jain RK. 1996. Delivery of molecular medicine to solid tumors. Science 271:1079-80
121. Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE. 1996. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res. 56:2626-32
122. Casey PJ. 1995. Protein lipidation in cell signaling. Science 268:221-25
123. Jefferson AB, Majerus PW. 1995. Properties of type II inositol polyphosphate 5-phosphatase. J. Biol. Chem. 270:9370-77
124. Angelis DAD, Braun PE. 1994. Isoprenylation of brain 2′, 3′-cyclic nucleotide 3′-phosphodiesterase modulates cell morphology. J. Neurosci. Res. 39:386-97
125. De Smedt F, Boom A, Pesesse X, Schiffman SN, Erneux C. 1996. Post-translational modification of human brain type I inositol-1,4,5-triphosphate 5-phosphatase by farnesylation. J. Biol. Chem. 271:10419-24